transcranial-magnetic-stimulation

Transcranial Magnetic Stimulation (TMS) for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">transcranial-magnetic-stimulation</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Low-frequency rTMS</td>
<td>1 Hz</td>
</tr>
<tr>
<td class="label">High-frequency rTMS</td>
<td>5-20 Hz</td>
</tr>
<tr>
<td class="label">Theta burst stimulation (TBS)</td>
<td>50 Hz bursts at 5 Hz</td>
</tr>
<tr>
<td class="label">Deep TMS (H-coil)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>10 Hz</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>80-120% resting motor threshold</td>
</tr>
<tr>
<td class="label">Pulses</td>
<td>2,000 per session</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>20 (daily, 5 days/week for 4 weeks)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>M1 (hand area), contralateral to most affected side</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>3 pulses at 50 Hz, repeated at 5 Hz</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>3 minutes (600 pulses)</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>10-20</td>
</tr>
<tr>
<td class="label">Target</td>
<td>M1 or DLPFC</td>
</tr>
<tr>
<td class="label"

Transcranial Magnetic Stimulation (TMS) for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">transcranial-magnetic-stimulation</th>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Low-frequency rTMS</td>
<td>1 Hz</td>
</tr>
<tr>
<td class="label">High-frequency rTMS</td>
<td>5-20 Hz</td>
</tr>
<tr>
<td class="label">Theta burst stimulation (TBS)</td>
<td>50 Hz bursts at 5 Hz</td>
</tr>
<tr>
<td class="label">Deep TMS (H-coil)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>10 Hz</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>80-120% resting motor threshold</td>
</tr>
<tr>
<td class="label">Pulses</td>
<td>2,000 per session</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>20 (daily, 5 days/week for 4 weeks)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>M1 (hand area), contralateral to most affected side</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Pattern</td>
<td>3 pulses at 50 Hz, repeated at 5 Hz</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>3 minutes (600 pulses)</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>10-20</td>
</tr>
<tr>
<td class="label">Target</td>
<td>M1 or DLPFC</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Faster administration</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Coil</td>
<td>H1 or H2</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>10-20 Hz</td>
</tr>
<tr>
<td class="label">Intensity</td>
<td>100-120% MT</td>
</tr>
<tr>
<td class="label">Pulses</td>
<td>1,800-3,000 per session</td>
</tr>
<tr>
<td class="label">Sessions</td>
<td>20-30</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Bilateral motor/prefrontal cortex</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Bradykinesia</td>
<td>M1 (contralateral)</td>
</tr>
<tr>
<td class="label">Rigidity</td>
<td>M1 + premotor</td>
</tr>
<tr>
<td class="label">Tremor</td>
<td>M1 + cerebellum</td>
</tr>
<tr>
<td class="label">Gait</td>
<td>DLPFC + M1</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>Left DLPFC</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>DLPFC bilaterally</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04897994</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT05211860</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT05387278</td>
<td>II</td>
</tr>
<tr>
<td class="label">NCT05564168</td>
<td>I/II</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Low Frequency</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>≤1 Hz</td>
</tr>
<tr>
<td class="label">Pulses</td>
<td>1-600</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>20-60 min</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Inhibition</td>
</tr>
</table>

Introduction

Overview

Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses rapidly changing magnetic fields to induce electrical currents in cortical [neurons](/entities/neurons). Repetitive TMS (rTMS) can produce lasting changes in cortical excitability and [long-term-potentiation](/mechanisms/long-term-potentiation)—enhancing or suppressing neural activity depending on stimulation parameters—making it both a powerful research tool for probing brain circuit function and a potential therapeutic intervention for [neurodegenerative /diseases. [@cantone2014]

In the context of neurodegeneration, TMS serves dual roles: as a diagnostic biomarker revealing patterns of cortical excitability that can distinguish disease subtypes and predict progression, and as a therapeutic modality aimed at restoring disrupted circuit function and enhancing cognitive or motor performance. The U.S. FDA has cleared TMS devices for depression and OCD, and clinical trials are actively evaluating efficacy in [alzheimers](/diseases/alzheimers-disease) (AD), [parkinsons](/diseases/parkinsons-disease) (PD), [als](/diseases/amyotrophic-lateral-sclerosis) (ALS), and other conditions ([Cantone et al., 2014](https://pubmed.ncbi.nlm.nih.gov/23627752/)). [@ref]

• --

Principles of TMS

Single-Pulse and Paired-Pulse TMS

A brief, intense current through a coil placed on the scalp generates a magnetic field pulse (1-2 Tesla at the coil surface) that penetrates the skull and induces an electrical current in underlying [cortex](/brain-regions/cortex). Key neurophysiological measures include: [@di2006]

• Motor evoked potential (MEP): Amplitude and latency of the muscle response to a TMS pulse over motor [cortex](/brain-regions/cortex), reflecting corticospinal excitability
• Resting motor threshold (RMT): Minimum stimulation intensity to produce MEPs, reflecting cortical membrane excitability
• Short-interval intracortical inhibition (SICI): Paired-pulse measure reflecting GABAergic inhibition (GABA_A receptor-mediated)
• Intracortical facilitation (ICF): Paired-pulse measure reflecting glutamatergic excitation
• Short-afferent inhibition (SAI): Reflects cholinergic circuits in sensorimotor [cortex](/brain-regions/cortex)
• Long-interval intracortical inhibition (LICI): Reflects GABA_B receptor-mediated inhibition

Repetitive TMS (rTMS)

Repeated trains of TMS pulses produce effects that outlast the stimulation period: [@benussi2023]

These plasticity-like effects are mediated by [nmda-receptor](/entities/nmda-receptor) receptor] receptor]-dependent mechanisms analogous to [long-term-potentiation](/mechanisms/long-term-potentiation) ([long-term-potentiation](/mechanisms/long-term-potentiation) and long-term depression (LTD) ([Huang et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15637374/)). [@lefaucheur2020]

• --

TMS as a Diagnostic Tool in Neurodegeneration

Alzheimer's Disease

TMS reveals a distinctive neurophysiological signature in AD: [@refa]

• Reduced RMT: Cortical hyperexcitability, reflecting loss of cholinergic and GABAergic inhibition
• Reduced SICI: Impaired intracortical inhibition (GABA_A circuit dysfunction)
• Impaired SAI: Specific deficit in cholinergic short-afferent inhibition—the most reliable TMS biomarker of AD, normalizable by [cholinesterase-inhibitors](/entities/cholinesterase-inhibitors) ([Di Lazzaro et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16553614/))
• Enhanced [long-term-potentiation](/mechanisms/long-term-potentiation)-like plasticity (early): Compensatory enhancement in mild cognitive impairment (MCI)
• Impaired [long-term-potentiation](/mechanisms/long-term-potentiation)-like plasticity (late): Failed plasticity in moderate-severe AD

Parkinson's Disease

In PD, TMS reveals:

• Normal or increased RMT: Unlike AD
• Reduced SICI: Reflecting impaired dopaminergic modulation of GABAergic inhibition
• Abnormal cortical plasticity: Impaired [long-term-potentiation](/mechanisms/long-term-potentiation)-like and LTD-like responses, reflecting striatal and cortical circuit dysfunction
• Improved SICI with levodopa: [levodopa](/therapeutics/levodopa) and [dopamine-agonists](/therapeutics/dopamine-agonists) partially normalize SICI deficits

Amyotrophic Lateral Sclerosis

TMS is a valuable diagnostic and prognostic tool in ALS:

• Cortical hyperexcitability: Reduced RMT, reduced SICI, and increased ICF appear early—often before clinical weakness—and distinguish ALS from mimics
• Central motor conduction time: Prolonged in ALS, reflecting corticospinal tract degeneration
• Split hand index: TMS-derived measure of differential hand muscle involvement, characteristic of ALS
• Threshold tracking TMS: A specialized technique providing quantitative cortical excitability profiles that can identify ALS in the diagnostic evaluation ([Vucic et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18367485/))

Huntington's Disease

[huntington-pathway](/mechanisms/huntington-pathway) shows:

• Reduced SICI: Progressive loss of intracortical inhibition correlating with disease stage
• Impaired cortical plasticity: Abnormal [long-term-potentiation](/mechanisms/long-term-potentiation)/LTD-like responses to rTMS protocols
• Prolonged cortical silent period: Reflecting altered GABA_B signaling
• --

Therapeutic Applications of TMS

Parkinson's Disease

TMS has been extensively studied for PD motor symptoms with moderate to strong evidence:

Motor Cortex (M1) Stimulation

• High-frequency rTMS (5-25 Hz): Improves bradykinesia and rigidity [@khedr2024]
• Target: Primary motor cortex, contralateral to most affected side
• Effects: 20-40% improvement in UPDRS motor scores in meta-analyses
• Mechanism: Increased cortical excitability, enhanced dopaminergic transmission

Prefrontal Cortex (DLPFC) Stimulation

• High-frequency rTMS: Improves gait and freezing [@lomarev2024]
• Target: Left DLPFC for motor aspects
• Effects on non-motor symptoms: Depression, cognition, fatigue
• Combination with medication: May reduce levodopa requirements

Subthalamic Nucleus (STN) Region

• Stimulation targeting STN: May improve motor symptoms [@shin2024]
• Rationale: Mimics effects of invasive DBS
• Evidence: Limited but promising
• Safety: Requires precise targeting

Corticobasal Syndrome (CBS)

Evidence for TMS in CBS is more limited but growing:

• Motor cortex stimulation: May improve apraxia and cortical symptoms [@bucur2024]
• Cognitive/behavioral symptoms: DLPFC stimulation may help executive dysfunction
• Combination with physical therapy: Enhanced motor learning
• Research status: Phase II trials ongoing

Progressive Supranuclear Palsy (PSP)

TMS applications in PSP focus on:

• Balance and gait: Prefrontal and parietal stimulation [@brusa2024]
• Cognitive symptoms: DLPFC targeting for executive dysfunction
• Eye movement disorders: Limited evidence for saccadic improvement
• Caution: Neurodegenerative progression may limit benefits

Treatment Protocols for Parkinsonism

Standard rTMS Protocol for PD Motor Symptoms

Theta Burst Protocol

Deep TMS Protocol

Targeting Strategy by Symptom

Clinical Evidence

Meta-Analyses and Systematic Reviews

Key Clinical Trials

Evidence by Indication

Parkinson's Disease:

• Strong evidence (Level A) for motor symptom improvement
• Moderate evidence for gait and freezing
• Growing evidence for non-motor symptoms
• Effects lasting 1-3 months post-treatment

• Limited but promising evidence
• Case series show improvement in apraxia
• May help with cortical symptoms
• More RCTs needed

• Preliminary evidence for balance/gait
• Cognitive effects being investigated
• Limited by disease progression
• Safety established

Personalized Treatment Considerations

For the atypical parkinsonism patient (50-year-old male, possible CBS/PSP, DAT scan confirmed dopamine loss, a-syn negative):

Rationale for TMS

Recommended Approach

Expected Outcomes

• Motor symptom improvement: 15-30% in UPDRS III
• May reduce levodopa requirements
• Cognitive effects variable
• Duration of benefits: 1-6 months

Emerging Technologies

Neuroimaging-Guided TMS

Personalized TMS protocols use structural MRI, fMRI, or EEG to:

• Identify optimal stimulation targets based on individual functional connectivity
• Adjust intensity based on cortical-to-coil distance
• Monitor real-time neural responses to optimize parameters

Transcranial Focused Ultrasound + TMS

Combining [focused-ultrasound](/therapeutics/focused-ultrasound) with TMS may enable non-invasive modulation of deeper brain structures beyond the reach of conventional TMS coils.

Transcranial Direct Current Stimulation (tDCS)

A complementary non-invasive stimulation technique using weak direct current (1-2 mA) to modulate cortical excitability. Anodal tDCS enhances excitability while cathodal tDCS reduces it. tDCS has been evaluated in AD, PD, and ALS with modest results.

Closed-Loop Stimulation

Adaptive stimulation systems that monitor ongoing neural activity (via EEG) and deliver TMS pulses timed to specific brain states (e.g., theta phase) to maximize plasticity-enhancing effects.

• --

Safety and Limitations

Safety Profile

TMS is generally safe with few serious adverse effects:

• Common: Scalp discomfort, headache, mild facial twitching during stimulation
• Uncommon: Syncope (vasovagal)
• Rare: Seizure induction (primarily with high-frequency protocols; risk ~0.01%)
• Contraindications: Metallic implants near the coil, cochlear implants, epilepsy history

Limitations

• --

Current Research Directions

• --

See Also

• [deep-brain-stimulation](/therapeutics/deep-brain-stimulation)
• [transcranial-direct-current-stimulation-tdcs](/therapeutics/transcranial-direct-current-stimulation-tdcs)
• [focused-ultrasound](/therapeutics/focused-ultrasound)
• [vagus-nerve-stimulation-parkinsons-disease](/therapeutics/vagus-nerve-stimulation-parkinsons-disease)
• [spinal-cord-stimulation-parkinsons](/therapeutics/spinal-cord-stimulation-parkinsons)

Background

The study of Transcranial Magnetic Stimulation (Tms) For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [ClinicalTrials.gov: TMS Parkinsonism Studies](https://clinicaltrials.gov/search?cond=parkinsonian+disorders&intr=TMS)
• [TMS Society](https://www.tmssociety.org)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Mechanism of Action

Stimulation Parameters

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering](/hypothesis/h-24e08335) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TDC
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;